Chrysalis, a leading GMP cleanroom hosting and support services partner for advanced therapy and biopharma innovators, is pleased to announce the appointment of Adam Bartley as its Chief Operating Officer (COO).
In this role, Bartley will lead day-to-day operations and growth across Chrysalis’ cleanroom infrastructure, environmental monitoring, and support service teams. He joins the executive team as Chrysalis strengthens its operational capabilities to support an expanding portfolio of advanced therapy clients.
Bartley brings over 24 years of leadership experience in biopharmaceutical operations. Over the course of his career, Adam has contributed to the success of globally recognized companies including Wyeth, Shire, and Sanofi, where he gained deep expertise in advancing innovative therapies and supporting organizational growth. Most notably, he joins Chrysalis not just as an industry veteran, but as a former client, having previously partnered with the company to launch and operate cleanroom-based manufacturing operations at Editas Medicine.
“Adam’s deep operational and leadership experience is only strengthened by his unique understanding of our Chrysalis operating model,” said Sarah Stevens, CEO of Chrysalis. “He’s lived our customer experience first-hand, and brings a pragmatic, continuous improvement mindset that complements our ability to enable speed, quality, and flexibility for our customers.”
As a former Senior Vice President of Business Operations at Editas Medicine, Bartley led programs through tech transfer and facility startup, while leveraging the Chrysalis’ cleanroom and support infrastructure. His experience as a customer will further strengthen our service delivery and growth.
“As a client, I saw the value Chrysalis brings to growing biotechs – cutting out complexity and significant capital expenditure so teams can focus on science and execution,” said Bartley. “I’m excited to now be on the inside, helping scale that model and push operational boundaries to support even more clients.”
Bartley’s appointment reflects Chrysalis’ continued investment in people and operational excellence as it expands its support of biopharma clients from development through GMP clinical and commercial production.
